{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ajovy",
    "query": {
      "intervention": "Ajovy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T19:38:58.909Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05724771",
      "title": "COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Migraine, Headache"
      ],
      "interventions": [
        {
          "name": "Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chicago Headache Center & Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-01-26",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05724771"
    },
    {
      "nct_id": "NCT04547179",
      "title": "Medicinal vs. Orthotic Comparison for Migraine Prevention: A Double-Blind Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Fremanezumab-Vfrm",
          "type": "DRUG"
        },
        {
          "name": "BLAfit®",
          "type": "DEVICE"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Manhattan Beach Orthodontics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2021-02-01",
      "completion_date": "2021-12-01",
      "has_results": false,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 1,
      "location_summary": "Manhattan Beach, California",
      "locations": [
        {
          "city": "Manhattan Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04547179"
    },
    {
      "nct_id": "NCT06173661",
      "title": "Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine",
        "Menstrual Migraine",
        "Menstrually Related Migraine"
      ],
      "interventions": [
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2024-03-01",
      "completion_date": "2026-07-13",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 1,
      "location_summary": "Chestnut Hill, Massachusetts",
      "locations": [
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06173661"
    },
    {
      "nct_id": "NCT04461795",
      "title": "Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David True",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-12-01",
      "completion_date": "2022-01-10",
      "has_results": true,
      "last_update_posted_date": "2022-04-13",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 2,
      "location_summary": "City of Saint Peters, Missouri • Springfield, Missouri",
      "locations": [
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04461795"
    },
    {
      "nct_id": "NCT04693533",
      "title": "Fremanezumab, Migraine and Sleep",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine Disorders",
        "Sleep Disorder"
      ],
      "interventions": [
        {
          "name": "Fremanezumab Prefilled Syringe [Ajovy]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2021-07-29",
      "completion_date": "2024-04-01",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04693533"
    },
    {
      "nct_id": "NCT06212661",
      "title": "Migraine Medication Effects on Urinary Symptoms",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Overactive Bladder",
        "Bladder Pain Syndrome",
        "Migraine Disorders",
        "Overactive Bladder Syndrome",
        "Overactive Detrusor",
        "Migraine",
        "Interstitial Cystitis"
      ],
      "interventions": [
        {
          "name": "Ubrogepant",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant",
          "type": "DRUG"
        },
        {
          "name": "Atogepant",
          "type": "DRUG"
        },
        {
          "name": "Eptinezumab",
          "type": "DRUG"
        },
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Botulinum toxin A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2024-04-05",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06212661"
    },
    {
      "nct_id": "NCT07832266",
      "title": "Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cranial Nerve Injury",
        "Oropharyngeal Cancer"
      ],
      "interventions": [
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Ajovy",
          "type": "DRUG"
        },
        {
          "name": "Manual Therapy",
          "type": "OTHER"
        },
        {
          "name": "IOPI device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2027-03-01",
      "completion_date": "2032-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07832266"
    },
    {
      "nct_id": "NCT05284019",
      "title": "Real World Effectiveness of Eptinezumab in Participants With Migraine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Eptinezumab",
          "type": "DRUG"
        },
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Onabotulinumtoxin-A",
          "type": "DRUG"
        },
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2022-03-04",
      "completion_date": "2023-04-14",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-09-24T19:38:58.909Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Ridgeland",
          "state": "Mississippi"
        },
        {
          "city": "City of Saint Peters",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05284019"
    }
  ]
}